Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin versus pioglitazone crossover study in type 2 diabetes
ACTRN12618001907235Phase 4Completed
- Sponsor
- The University of Auckland
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vildagliptin and pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The University of Auckland. Primary endpoint: HbA1c. Started Mar 2019; status: completed.
02
Drugs
vildagliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12618001907235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001907235.